Emerald Advisers, LLC Passage Bio, Inc. Transaction History

Emerald Advisers, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 02, 2022	SELL	$6.24 - $10.2 $877,961 - $1.44 Million	-140,699 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$9.73 - $15.52 $3.46 Million - $5.51 Million	-355,232 Reduced 71.63%	140,699 $1.4 Million
Q2 2021 Jul 29, 2021	SELL	$12.44 - $19.45 $44,908 - $70,214	-3,610 Reduced 0.72%	495,931 $6.57 Million
Q1 2021 Apr 29, 2021	BUY	$16.24 - $29.83 $2.58 Million - $4.74 Million	158,843 Added 46.62%	499,541 $8.73 Million
Q4 2020 Jan 29, 2021	SELL	$14.28 - $29.73 $13,266 - $27,619	-929 Reduced 0.27%	340,698 $8.71 Million
Q3 2020 Oct 28, 2020	SELL	$12.39 - $26.15 $137,727 - $290,683	-11,116 Reduced 3.15%	341,627 $4.48 Million
Q2 2020 Jul 28, 2020	SELL	$14.59 - $36.07 $27,108 - $67,018	-1,858 Reduced 0.52%	352,743 $9.64 Million
Q1 2020 Apr 30, 2020	BUY	$8.86 - $22.2 $3.14 Million - $7.87 Million	354,601 New	354,601 $5.59 Million

38.7M

7.7K

Ticker PASG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,463,200
Market Cap $32.1M
Description
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

Stay updated on Emerald Advisers, LLC with notifications on news.